XORTX Therapeutics Inc. announced the closing of a private placement of units, raising US$114,500. Each unit included one common share and one common share purchase warrant. The company plans to use the proceeds for gout programs and general corporate purposes. The securities issued are subject to a statutory hold period and are not registered under the U.S. Securities Act. XORTX is a pharmaceutical company focused on developing therapies for gout and kidney diseases. The forward-looking statements in the news release include the company’s current and future financing plans, business objectives, and operations. Additional information is available on their website.

Read more at GlobeNewswire: XORTX Completes USD $114,500 Private Placement